Prognosis of unfavorable course of ulcerative colitis as indication for anticytokine therapy
Abstract
Aim of investigation. To outline predictive model for unfavorable course of ulcerative colitis (UC).
Material and methods. Overall 232 patients with UC were included in original study, 84 of them had favourable and 148 – unfavorable course of disease.
Results. Prognostic system for various variants of course of UC and its complications, 27 most significant clinical signs of disease based on differentiated clinical and statistical evaluation was submitted. To define indications for «top down» therapy with application of TNF-α blockers clinically approved algorithm of prognostic decisions for development of favorable (uncomplicated, rarely relapsing) and unfavorable (frequently relapsing, continuous, steroiddependent) variants of disease, and its complications was stated. Basing on high scores of sensitivity (accuracy) and specificity of prognosis, that were received, data proving potential of indications for early anticytokine treatment by infliximab to avoid unfavorable course and complications of ulcerative colitis are presented.
About the Authors
A. Yu. Baranovsky
State educational government-financed institution of higher professional education Mechnikov North-Western State medical University
Russian Federation
Russian Federation
E. A. Kondrashina
State educational government-financed institution of higher professional education Mechnikov North-Western State medical University
Russian Federation
Russian Federation
A. G. Kharitonov
State educational government-financed institution of higher professional education Mechnikov North-Western State medical University
Russian Federation
Russian Federation
References
1. Барановский А.Ю. Прогнозирование течения, исходов и осложнений язвенной болезни желудка: Автореф. дис. ... д-ра мед. наук. – СПб, 1988. – 44 с.
2. Назаренко Л.И. Мигрирующие гастродуоденальные язвы: Автореф. дис. ... д-ра мед. наук. – СПб, 2000. – 42 с.
3. Altman D.G., Bland J.M. Quartiles, quintiles, centiles, and other quantiles // BMJ. – Vol. 309, N 6960. – P. 996.
4. Armuzzi A., Pascalis B., Lupascu A. et al. Infliximab in the treatment of steroid-dependent ulcerative colitis // Eur. Rev. Med. Pharmacol. Sci. – 2004. – Vol. 8. – P. 231–233.
5. Chaparro M., Burgueno P., Iglesias E. et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study // Aliment. Pharmacol. Ther. – 2012. – Vol.35, N 2. – P. 275–283.
6. Cui D.J. Early aggressive therapy for severe extensive ulcerative colitis // World J. Gastroenterol. – 2009. – Vol.15, N 33. – P. 4218–4219.
7. Deeks J.J., Altman D.G. Diagnostic tests 4: likelihood ratios // BMJ. – 2004. – Vol. 329, N 7458. – P.168– 169.
8. Roediger W.E.W., Moore J., Babidge W. Colonic sulfide in pathogenesis and treatment of ulcerative colitis // Dig. Dis. Sci. – 2007. – Vol. 42, N 8. – P. 1571–1579.
9. Russo E.A., Harris A.W., Campbell S. et al. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England // Aliment. Pharmacol. Ther. – 2009. – Vol. 29. – P. 308–314.
10. Thorsteinsdottir S., Gudjonsson Th., Nielsen O.H. et al. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis// Nature Rev. Gastroenterol. Hepatol. – 2011. – Vol. 8. – P. 395–404.
11. Tüzün А., Erdil А., İnal V. et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease// Clin. Biochem. – 2002. – Vol. 35, N 7. – P. 569–572.
Review
For citations:
Baranovsky A.Yu., Kondrashina E.A., Kharitonov A.G. Prognosis of unfavorable course of ulcerative colitis as indication for anticytokine therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(3):63-69. (In Russ.)
Views:
77
Email this article 
